Glaucoma Eyeyag laser PINCT07195370
Testing YAG Laser Iridotomy for Primary Angle-Closure Glaucoma
A study testing peripheral iridotomy in people with Glaucoma Eye and Angle Closure Glaucoma, run by Isfahan University of Medical Sciences at 1 site in Iran.
Trial summary
This study evaluates the effectiveness and safety of YAG laser peripheral iridotomy performed at two different locations (temporal and inferior) in patients with primary angle-closure glaucoma, a leading cause of blindness worldwide. Read more about this study
- Who is it for?
- Ages 24 years and older
- Conditions the study is for
- Glaucoma Eye, Angle Closure Glaucoma
- What is being tested?
- peripheral iridotomy
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 150 participants
- Where
- 1 siteIran
- Study dates
- 1 May 2025to 1 Jan 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 24 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
None listed.
Who cannot join
- Active eye diseases (e.g., infection or inflammation).
- Advanced cataracts or lens-related issues.
- Severe visual impairment (e.g., less than 20/200 vision).
- Uncontrolled systemic diseases (e.g., diabetes or cardiovascular disease).
- Pregnancy or breastfeeding.
- Previous eye surgery (except for minor procedures).
- Inability to follow-up with scheduled visits.
- -
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluation of the Effectiveness of YAG Laser Iridotomy in Patients With Primary Angle-Closure: Temporal Peripheral Iridotomy Compared to Inferior Peripheral Iridotomy
This study evaluates the effectiveness and safety of YAG laser peripheral iridotomy performed at two different locations (temporal and inferior) in patients with primary angle-closure glaucoma, a leading cause of blindness worldwide. Patients visiting the glaucoma clinic at Feiz Hospital who are candidates for peripheral iridotomy will participate. In each patient, one eye will receive a temporal iridotomy, and the other eye will receive an inferior iridotomy, with patients unaware of the location used in each eye. The study will measure outcomes such as laser power, intraocular pressure, visual symptoms, and complications over six months to determine which approach is more effective and safer.
- Conditions
- Glaucoma Eye, Angle Closure Glaucoma
- Being tested
- peripheral iridotomy
- Keywords
- Primary Angle-Closure Glaucoma
- Medical subject headings
- Glaucoma, Angle-Closure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
peripheral iridotomyOther
This procedure involves using a neodymium-doped yttrium aluminum garnet (YAG) laser to create a small hole in the temporal region of the iris in one eye. It aims to relieve intraocular pressure in patients with primary angle-closure glaucoma by improving the flow of aqueous humor. The procedure is performed under local anesthesia in a clinical setting, with patients unaware of which eye receives this treatment. Outcomes, including laser power, intraocular pressure, visual symptoms, and complications, are monitored over six months.
| Study group | Role | What they receive |
|---|---|---|
| Description: YAG laser peripheral iridotomy performed in the temporal region of one eye. Arm 2 Title | Other | Not described Receives: Other: peripheral iridotomy |
What is being measured
The primary outcome is the main question the study is designed to answer.
adverse events
Surgical and postoperative complications (e.g., bleeding, infection, or changes in intraocular pressure).
Measured: 1 day, 1 week, 1month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Sep 2025
- Study start1 May 2025
- Primary completion1 Oct 2025 (estimated)
- Study completion1 Jan 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Glaucoma EyeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Isfahan University of Medical Sciences
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Afsaneh Naderi Beni, Isfahan University of Medical Sciences
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07195370
- Sponsor's protocol ID
- feiz-123456
- Other IDs
- IR.MUI.MED.REC.1401.153
- Acronym
- yag laser PI
- Status last verified
- Sep 2025
- First submitted
- 26 Aug 2025
- Last updated
- 26 Sep 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Effectiveness of YAG Laser Iridotomy in Patients With Primary Angle-Closure: Temporal Peripheral Iridotomy Compared to Inferior Peripheral Iridotomy
- ClinicalTrials.gov ID
- NCT07195370
- Acronym / sponsor ID
- yag laser PI / feiz-123456
- Conditions
- Glaucoma Eye, Angle Closure Glaucoma
- Keywords
- Primary Angle-Closure Glaucoma
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- Isfahan University of Medical SciencesUniversity, hospital or other
- Study start
- 1 May 2025 (actual)
- Primary completion
- 1 Oct 2025 (estimated)
- Study completion
- 1 Jan 2026 (estimated)
- First posted
- 26 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluates the effectiveness and safety of YAG laser peripheral iridotomy performed at two different locations (temporal and inferior) in patients with primary angle-closure glaucoma, a leading cause of blindness worldwide. Patients visiting the glaucoma clinic at Feiz Hospital who are candidates for peripheral iridotomy will participate. In each patient, one eye will receive a temporal iridotomy, and the other eye will receive an inferior iridotomy, with patients unaware of the location used in each eye. The study will measure outcomes such as laser power, intraocular pressure, visual symptoms, and complications over six months to determine which approach is more effective and safer.
Study design
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Description: YAG laser peripheral iridotomy performed in the temporal region of one eye. Arm 2 Title | Other | Other: peripheral iridotomy |
Who may qualify
- Ages
- 24 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (0 listed)
Key exclusion criteria (8 listed)
- Active eye diseases (e.g., infection or inflammation).
- Advanced cataracts or lens-related issues.
- Severe visual impairment (e.g., less than 20/200 vision).
- Uncontrolled systemic diseases (e.g., diabetes or cardiovascular disease).
- Pregnancy or breastfeeding.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| peripheral iridotomyThis procedure involves using a neodymium-doped yttrium aluminum garnet (YAG) laser to create a small hole in the temporal region of the iris in one eye. It aims to relieve intraocular pressure in patients with primary angle-closure glaucoma by improving the flow of aqueous humor. The procedure is performed under local anesthesia in a clinical setting, with patients unaware of which eye receives this treatment. Outcomes, including laser power, intraocular pressure, visual symptoms, and complications, are monitored over six months. | Other | Description: YAG laser peripheral iridotomy performed in the temporal region of one eye. Arm 2 Title |
Primary outcome
adverse events
Time frame: 1 day, 1 week, 1month
Surgical and postoperative complications (e.g., bleeding, infection, or changes in intraocular pressure).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Sep 2025.
- Individual participant dataSharing planned: No
Related trials for Glaucoma Eye
Active, not recruitingObservational study
Impact of Glaucoma and Visual Field Loss on Life Space
Primary Open-angle Glaucoma
Active, not recruitingObservational study
Glaucoma, Visual Field Loss, and Their Association With Life Space in Older Adults
Primary Open Angle Glaucoma
Not yet recruitingPhase 2
VGFTe-(HD)-OD-2566: Adjunctive Aflibercept Ahmed Glaucoma Valve (AAA) Study
Glaucoma
Not yet recruitingPhase 4
Iopidine to Decrease Intraocular Pressure Rise After Injections
Macular Degeneration, Diabetic Retinopathy
Recruiting
Timing of Glaucoma Drainage Device With Boston Keratoprosthesis
Corneal Transplantation, Glaucoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing peripheral iridotomy in people with Glaucoma Eye and Angle Closure Glaucoma, run by Isfahan University of Medical Sciences at 1 site in Iran.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 26 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Iran. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
adverse events (time frame: 1 day, 1 week, 1month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Sep 2025.